[Retracted] Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis

Table 3

Survival prognosis-linked factor assessments.

Factor	Overall survival				Progression-free survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95% CI)		HR (95% CI)		HR (95% CI)		HR (95% CI)
Sex
Female/male	1.114 (0.524-2.365)	0.779			0.788 (0.466-1.330)	0.372
Age (years)
<60/≥60	0.908 (0.526-1.566)	0.728			0.870 (0.580-1.307)	0.504
HBsAg
Positive/negative	0.359 (0.111-1.157)	0.086	0.173 (0.051-0.589)	0.005	0.748 (0.235-2.379)	0.622
Child-Pugh grade
B/A	2.018 (1.187-3.433)	0.010			1.082 (0.713-1.643)	0.712
AFP level (ug/L)
≥400/<400	2.052 (1.192-3.534)	0.010	1.923 (1.069-3.460)	0.029	1.514 (0.995-2.304)	0.053	1.548 (1.009-2.374)	0.045
Number of tumors
>3/≤3	0.653 (0.384-1.112)	0.117			1.122 (0.754-1.667)	0.571
Tumor size (cm)
≥5/<5	0.888 (0.521-1.515)	0.063			1.178 (0.791-1.754)	0.420
Tumor thrombus
Yes/no	6.911 (3.425-13.942)	<0.01	4.944 (2.300-10.628)	<0.01	2.004 (1.083-3.708)	0.027
Lymph node metastasis
Yes/no	2.322 (1.211-4.451)	0.011			1.281 (0.758-2.164)	0.356
Distant metastasis
Yes/no	1.673 (0.706-3.967)	0.243			1.199 (0.622-2.313)	0.587
Treatment option
cTACE/H101-TACE	0.544 (0.300-0.989)	0.046			0.649 (0.423-0.996)	0.048
BCLC
C/B	2.999 (1.705-5.272)	<0.01			1.285 (0.834 -1.980)	0.255
ECOG
1/0	2.664 (1.520-4.669)	<0.01	2.300 (1.274-4.152)	0.006	1.289 (0.815-2.039)	0.278	1.207 (0.760-1.919)	0.4255
2/0	9.06 (2.673-30.705)	<0.01	7.407 (1.984-27.653)	0.003	9.397 (2.750-32.107)	0.004	10.713 (3.100-37.028)	<0.01

Abbreviations: ECOG: Eastern Cooperative Oncology Cohort; BCLC: Barcelona clinic liver cancer; AFP: alpha-fetoprotein.